Opti
-
Interest high for novel treatment options in development for metastatic breast cancer
Global oncology study highlights similarities, contrasts in treatment of breast cancer across the United States, Europe and Japan.
Opti | 25 August 2011
-
Subcutaneous ORENCIA provides an additional administration option
Bristol-Myers Squibb Company ( BMS )’s phase 3 clinical data show that a weekly subcutaneous injection of an investigational formulation of ORENCIA (abatacept), following a single intravenous (IV) loading dose, provided an improvement in disease ac…
Opti | 08 March 2011
-
Dorton Analytical: optimised user configurable syringe mechanism
Available from Dorton Analytical, the Legato 270 Syringe Pump has an optimised user configurable syringe mechanism designed to uniquely deliver a full volume in infuse and withdraw modes whether using small or large syringes. This reconfigurable mec…
Opti | 01 October 2010
-
Optimism over Australia election
Lisette Oversteegen, lead analyst from Datamonitor , comments on the impact of Australia’ election. Now that the Labor party has claimed a narrow victory, the pharmaceutical industry has reason to be optimistic about the Memorandum of Understand…
Opti | 22 September 2010
-
Adopting cultural adaptation
Cultural adaptation can maximise the return on investment for multinational clinical research.
Opti | 01 September 2010
-
GSK exercises option on Anacor's GSK ‘052
Anacor and GlaxoSmithKline (GSK) announce that GSK has exercised its option to obtain an exclusive licence to develop and commercialise GSK2251052 (GSK ‘052), formerly known as AN3365. GSK ‘052 is a novel, systemic antibiotic derived from Anacor…
Opti | 07 August 2010
-
Screening plates identify optimum scavengers
Biotage announces the introduction of ExploraSep 96-well screening plates to identify optimum scavengers. The four different screening plates deliver 128 selective resins based on high-performance, molecularly imprinted polymers (MIP). Biotage p…
Opti | 20 July 2010
-
InVitria Optimizes Hybridoma Cell Culture
InVitria’s launch of Zap-Hybridoma provides a solution for hybridoma cell culture. The solution was created to improve monoclonal antibody productivity and deliver easier purifi cation of the target product. It was developed as an answer t…
Opti | 01 May 2010
-
Biotage Reduces Solvent Use in Flash Purification
Biotage, a supplier of tools and technology for medicinal and analytical chemistry, has announced the launch of enhanced Gradient Optimization (GO) technology for their Isolera flash purification product line. This technology can reduce solvent use a…
Opti | 19 April 2010
-
Warwick Offers Cost-Effective Sample Screening Service
Warwick Analytical Service (WAS) has developed an Inductively Coupled Plasma - Optical Emission Spectrometry (ICP-OES) methodology that enables it to cost effectively screen samples for up to 70 elements. Developed to provide a rapid semi quantita…
Opti | 05 April 2010
